-
公开(公告)号：US20100035971A1
公开(公告)日：2010-02-11
申请号：US12086712
申请日：2006-12-21
申请人： Annamari Ranki , Sonja Hahtola , Leena Karenko , Soile Tuomela , Riitta Lahesmaa , Kai J.E. Krohn
发明人： Annamari Ranki , Sonja Hahtola , Leena Karenko , Soile Tuomela , Riitta Lahesmaa , Kai J.E. Krohn
IPC分类号： A61K31/7088 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158
摘要： The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products. The present invention further relates to a novel test kit, the kit comprising the necessary means for detecting one or more genes, gene fragments or gene products. The present invention also relates to a use of one or more genes, gene fragments or gene products for determination, diagnosis or follow-up of CTCL or CTCL subtype and for detection of the response to CTCL therapy. The present invention also relates to a use of one or more target molecules for CTCL therapy or for the preparation of a medicament for treating CTCL.
摘要翻译： 本发明涉及遗传学和肿瘤学领域，并提供了检测皮肤T细胞淋巴瘤（CTCL）或对CTCL敏感性的方法。 具体地说，本发明涉及一种诊断和追踪CTCL或CTCL亚型的新方法，该方法包括测定一种或多种基因，基因片段或基因产物的表达。 本发明还涉及检测对CTCL治疗的反应的新方法，所述方法包括测定生物样品中一种或多种基因或基因片段或基因产物的表达。 本发明还涉及一种开发或改进CTCL治疗或开发抗CTCL药物的新方法，该方法包括影响一种或几种基因或基因产物的筛选剂。 本发明还涉及一种治疗CTCL患者的新方法，该方法包括影响一种或几种基因或基因产物。 本发明还涉及一种新的测试试剂盒，该试剂盒包含检测一种或多种基因，基因片段或基因产物的必要手段。 本发明还涉及一种或多种基因，基因片段或基因产物用于测定，诊断或追踪CTCL或CTCL亚型以及检测对CTCL治疗的应答的用途。 本发明还涉及一种或多种靶分子用于CTCL治疗或制备用于治疗CTCL的药物的用途。
-
公开(公告)号：US07803532B2
公开(公告)日：2010-09-28
申请号：US10502638
申请日：2003-01-24
申请人： Annamari Ranki , Leena Karenko , Marketta Kähkönen , Ritva Karhu , Tapio Visakorpi , Boguslaw Nedoszytko
发明人： Annamari Ranki , Leena Karenko , Marketta Kähkönen , Ritva Karhu , Tapio Visakorpi , Boguslaw Nedoszytko
CPC分类号： C12Q1/6886 , C12Q2600/156
摘要： The present invention relates to novel methods for the diagnosis and therapy of lymphoproliferative diseases. Specifically, the present invention relates to novel methods for the diagnosis and therapy taking advantage of the detection of chromosomal breakpoints in chromosome 12 and/or translocation of chromosomal material from chromosome 12, said chromosomal breakpoints and/or translocation(s) being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL). The present invention further relates to the use of neuron navigator 3 gene (NAV3) or an equivalent or functional fragment thereof involved in chromosomal breakpoints in chromosome 12 and/or translocations thereof, said gene and/or translocations thereof being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL), as a diagnostic and therapeutic agent. The present invention also relates to the development of therapy.
摘要翻译： 本发明涉及用于诊断和治疗淋巴组织增生性疾病的新方法。 具体地说，本发明涉及利用染色体12染色体断裂点检测和/或从染色体12染色体材料易位检测的诊断和治疗的新方法，所述染色体断裂点和/或易位与淋巴组织增生相关 疾病，如原发性皮肤T细胞淋巴瘤（CTCL）。 本发明还涉及使用神经元导航器3基因（NAV3）或其涉及染色体12和/或其易位中的染色体断裂点的等同或功能片段，所述基因和/或易位与淋巴组织增生性疾病相关，例如 作为原发性皮肤T细胞淋巴瘤（CTCL），作为诊断和治疗剂。 本发明还涉及治疗的发展。
-
公开(公告)号：US08143029B2
公开(公告)日：2012-03-27
申请号：US12086712
申请日：2006-12-21
申请人： Annamari Ranki , Sonja Hahtola , Leena Karenko , Soile Tuomela , Riitta Lahesmaa , Kai J. E Krohn
发明人： Annamari Ranki , Sonja Hahtola , Leena Karenko , Soile Tuomela , Riitta Lahesmaa , Kai J. E Krohn
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158
摘要： The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products. The present invention further relates to a novel test kit, the kit comprising the necessary means for detecting one or more genes, gene fragments or gene products. The present invention also relates to a use of one or more genes, gene fragments or gene products for determination, diagnosis or follow-up of CTCL or CTCL subtype and for detection of the response to CTCL therapy. The present invention also relates to a use of one or more target molecules for CTCL therapy or for the preparation of a medicament for treating CTCL.
摘要翻译： 本发明涉及遗传学和肿瘤学领域，并提供了检测皮肤T细胞淋巴瘤（CTCL）或对CTCL敏感性的方法。 具体地说，本发明涉及一种诊断和追踪CTCL或CTCL亚型的新方法，该方法包括测定一种或多种基因，基因片段或基因产物的表达。 本发明还涉及检测对CTCL治疗的反应的新方法，所述方法包括测定生物样品中一种或多种基因或基因片段或基因产物的表达。 本发明还涉及一种开发或改进CTCL治疗或开发抗CTCL药物的新方法，该方法包括影响一种或几种基因或基因产物的筛选剂。 本发明还涉及一种治疗CTCL患者的新方法，该方法包括影响一种或几种基因或基因产物。 本发明还涉及一种新的测试试剂盒，该试剂盒包含检测一种或多种基因，基因片段或基因产物的必要手段。 本发明还涉及一种或多种基因，基因片段或基因产物用于测定，诊断或追踪CTCL或CTCL亚型以及检测对CTCL治疗的应答的用途。 本发明还涉及一种或多种靶分子用于CTCL治疗或制备用于治疗CTCL的药物的用途。
-
公开(公告)号：US20050221309A1
公开(公告)日：2005-10-06
申请号：US10502638
申请日：2003-01-24
申请人： Annamari Ranki , Leena Karenko , Marketta Kahkonen , Ritva Karhu , Tapio Visakorpi , Boguslaw Nedoszytko
发明人： Annamari Ranki , Leena Karenko , Marketta Kahkonen , Ritva Karhu , Tapio Visakorpi , Boguslaw Nedoszytko
CPC分类号： C12Q1/6886 , C12Q2600/156
摘要： The present invention relates to novel methods for the diagnosis and therapy of lymphoproliferative diseases. Specifically, the present invention relates to novel methods for the diagnosis and therapy taking advantage of the detection of chromosomal breakpoints in chromosome 12 and/or translocation of chromosomal material from chromosome 12, said chromosomal breakpoints and/or translocation(s) being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL). The present invention further relates to the use of neuron navigator 3 gene (NAV3) or an equivalent or functional fragment thereof involved in chromosomal breakpoints in chromosome 12 and/or translocations thereof, said gene and/or translocations thereof being associated with lymphoproliferative diseases, such as primary cutaneous T-cell lymphomas (CTCL), as a diagnostic and therapeutic agent. The present invention also relates to the development of therapy.
摘要翻译： 本发明涉及用于诊断和治疗淋巴组织增生性疾病的新方法。 具体地说，本发明涉及利用染色体12染色体断裂点检测和/或从染色体12染色体材料易位检测的诊断和治疗的新方法，所述染色体断裂点和/或易位与淋巴组织增生相关 疾病，如原发性皮肤T细胞淋巴瘤（CTCL）。 本发明还涉及使用神经元导航器3基因（NAV3）或其涉及染色体12和/或其易位中的染色体断裂点的等同或功能片段，所述基因和/或易位与淋巴组织增生性疾病相关，例如 作为原发性皮肤T细胞淋巴瘤（CTCL），作为诊断和治疗剂。 本发明还涉及治疗的发展。
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
